Biomarkers (short for biological markers) are biological measures of a biological state. By definition, a biomarker is “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention.”

Biomarkers are the measures used to perform a clinical assessment such as blood pressure or cholesterol level and are used to monitor and predict health states in individuals or across populations so that appropriate therapeutic intervention can be planned.

Recently IQuity Inc. brought forth a new MS biomarker test which boasts a 90% accuracy curve towards multiple sclerosis.

Nashville-based life science technology company IQuity announced today that it has received orders from physicians for its groundbreaking RNA-based blood test, IsolateMS, which can dramatically speed up the process of diagnosing multiple sclerosis (MS) when administered at the earliest onset of symptoms.

“The team at IQuity is thrilled with the level of interest from physicians who see value in ordering the test for their patients,” said Dr. Chase Spurlock, CEO, and co-founder of IQuity. “isolates fills an unmet need in autoimmune diagnostics. By relying on the power of RNA, we can give providers critical information about the patient’s condition earlier than before.  We are also seeing strong interest from other researchers and pharmaceutical companies who are interested in collaborating with us as we advance our research.”

With an accuracy rate of more than 90 percent, IsolateMS helps physicians confirm a suspected MS diagnosis faster and enables them to start an effective treatment plan much sooner with the goal of reducing the average diagnosis time from months or years to just a matter of weeks.

“Neurologists and neuroimmunologists should embrace Isolate MS since it is the closest thing next to a lesional biopsy,” said Jagannadha (Jay) Avasarala, MD, Ph.D., associate professor of neurology at the USC School of Medicine in Greenville, South Carolina.

Currently, diagnostic methods for MS rely on measuring the progress of irreversible neurological damage. With IsolateMS, neurologists will have access to new information to help confirm suspected cases of MS.

Erika Lyons Richardson conducts a fascinating interview with Chase Spurlock CEO of IQuity Inc. and patients.